Clinical Trial

A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human Phase I, multi-center, open-label study of ANS03 in patients with advanced solid tumors. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS03 as monotherapy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-11-29; most recent amendment 2026-03-11.
Status change: Not Yet Recruiting → Recruiting 2025-03-18
Trial Details
NCT Number NCT06716138
Lead Sponsor Avistone Biotechnology Co., Ltd.
Conditions Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Enrollment 96 participants
Start Date 2025-03-06
Primary Completion 2027-12-30 (estimated)
Study Completion 2029-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-13